PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$116.28
as of October 20, 2026 -
YTD RETURNS14.71%
as of October 20, 2026 -
Total Net Assets$1.13B
as of October 20, 2026 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Overview
Why PPH
- Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
- Industry LeadersFavors established industry leaders with meaningful scale
- Global ScopeProvides exposure to U.S. and international equities for global industry representation
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Performance
Average Annual Total Returns* (%)
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | -3.28 | 0.50 | 7.51 | 23.60 | 13.35 | 10.67 | 8.69 | 10.00 |
| PPH (Market Price) | -3.19 | 0.67 | 7.58 | 23.72 | 13.37 | 10.65 | 8.70 | 10.09 |
| MVIS US Listed Pharmaceutical 25 Index | -3.26 | 0.55 | 7.32 | 23.42 | 13.00 | 10.31 | 8.44 | 9.81 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR | LIFE 12/20/11 | |
|---|---|---|---|---|---|---|---|---|
| PPH (NAV) | -3.28 | 0.50 | 7.51 | 23.60 | 13.35 | 10.67 | 8.69 | 10.00 |
| PPH (Market Price) | -3.19 | 0.67 | 7.58 | 23.72 | 13.37 | 10.65 | 8.70 | 10.09 |
| MVIS US Listed Pharmaceutical 25 Index | -3.26 | 0.55 | 7.32 | 23.42 | 13.00 | 10.31 | 8.44 | 9.81 |
Holdings
Book a 15-minute call to learn more about the holdings.
Daily Holdings (%) as of 10/20/2026
Download XLS|
Ticker
|
Holding Name |
% of Net Assets
|
Market Value (US$)
|
|---|---|---|---|
|
LLY |
Eli Lilly & Co |
21.60 |
233,244,873 |
|
MRK |
Merck & Co Inc |
12.79 |
138,109,269 |
|
NVO |
Novo Nordisk A/S |
5.47 |
59,058,487 |
|
PFE |
Pfizer Inc |
5.12 |
55,350,671 |
|
MCK |
Mckesson Corp |
4.92 |
53,098,566 |
|
TEVA |
Teva Pharmaceutical Industries Ltd |
4.61 |
49,812,082 |
|
BMY |
Bristol-Myers Squibb Co |
4.53 |
48,903,111 |
|
COR |
Cencora Inc |
4.52 |
48,796,174 |
|
GSK |
Gsk Plc |
4.43 |
47,850,869 |
|
HLN |
Haleon Plc |
3.92 |
42,372,674 |
|
ABBV |
Abbvie Inc |
3.77 |
40,714,027 |
|
NVS |
Novartis Ag |
3.66 |
39,492,855 |
|
AZN |
Astrazeneca Plc |
3.52 |
38,014,212 |
|
JNJ |
Johnson & Johnson |
3.18 |
34,316,959 |
|
SNY |
Sanofi Sa/France |
3.16 |
34,142,290 |
|
TAK |
Takeda Pharmaceutical Co Ltd |
2.82 |
30,410,156 |
|
ZTS |
Zoetis Inc |
2.66 |
28,779,983 |
|
VTRS |
Viatris Inc |
1.49 |
16,044,856 |
|
JAZZ |
Jazz Pharmaceuticals Plc |
1.15 |
12,380,765 |
|
CORT |
Corcept Therapeutics Inc |
0.73 |
7,903,694 |
|
AXSM |
Axsome Therapeutics Inc |
0.60 |
6,444,479 |
|
ELAN |
Elanco Animal Health Inc |
0.47 |
5,121,937 |
|
DFTX |
Definium Therapeutics Inc |
0.42 |
4,570,437 |
|
OGN |
Organon & Co |
0.27 |
2,945,479 |
|
PRGO |
Perrigo Co Plc |
0.11 |
1,186,377 |
|
-USD CASH- |
-- |
0.00 |
10,708 |
|
-- |
Other/Cash |
0.09 |
985,385 |
Portfolio
- Market Capitalization (%)
- Currency Exposure (%)
- Sector Weightings (%)
- Country Weightings (%)
Sector Weightings (%) as at 09/30/2026
-
Sector
% of Net Assets -
Health Care
99.62 -
Other/Cash
0.38
Country Weightings (%) as at 09/30/2026
-
Country
% of Net Assets -
United States
67.84 -
United Kingdom
11.75 -
Denmark
5.60 -
Israel
4.75 -
Switzerland
3.61 -
France
3.35 -
Japan
2.71 -
Other/Cash
0.38
Fees
Distributions
as of 10/21/2026
Quarterly
1.68%
1.25%
1.85%
Team
Resources
Regulatory Information
-
Name
Frequency - Annually
- Annually
-
Statement of Additional Information (SAI)
Annually - Annually
- Annually
Fund Documents
-
Name
Frequency -
PPH Fund Profile: A Perfect Prescription for Growth Portfolios
- Daily
-
VanEck Tax Information & Distributions
Annually -
NAV & Premium/Discount History
Daily - Annually
Thought Leadership
-
Name
Frequency